Generic placeholder image

Current Drug Safety

Author(s): Yara Dadalti Fragoso

DOI: 10.2174/1574886310666150421113154

DownloadDownload PDF Flyer Cite As
Survey of Latin American Neuroimmunologists on the Treatment of Multiple Sclerosis with Monoclonal Antibodies

Page: [217 - 220] Pages: 4

  • * (Excluding Mailing and Handling)

Abstract

Natalizumab and alemtuzumab are monoclonal antibodies approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). A third monoclonal antibody, daclizumab, should soon become another alternative for RRMS therapy. A group of 26 doctors working at specific MS Units in seven different Latin American countries participated in the present study. All 26 neurologists had experience with natalizumab for the treatment of MS and were willing to discuss strategies for improving this treatment. Most neurologists had no confidence in starting a patient on natalizumab and alemtuzumab, which are new and efficient drugs approved by North American, European and most Latin American health agencies. The Latin American specialists felt they were not properly informed on daclizumab. Specific pharmacovigilance programs for each of these monoclonal antibodies were considered very important by the neurologists, who were also willing to discuss these therapeutic options with peers from other countries.

Keywords: Alemtuzumab, daclizumab, Latin America, multiple sclerosis, natalizumab.

[1]
Giovannoni G, Gold R, Selmaj K, et al. Daclizumab high-yield processes in relapsing-remitting multiple sclerosis (SELECTION): a multicenter, randomized, double-blind extension trial. Lancet Neurol 2014; 13: 472-81.
[2]
Pfender N, Martin R. Daclizumab (anti-CD25) in multiple sclerosis. Exp Neurol 2014; 262 Pt A: 44-51.
[3]
Liu J, Wang LN, Zhan S, Xia Y. Daclizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev 2013; 12CD008127
[4]
Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics 2013; 10: 55-67.
[5]
He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H. Rituximab for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev 2013; 6; 12:: CD009130.
[6]
Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Exp Rev Neurother 2010; 10: 791-809.
[7]
Deiß A, Brecht I, Haarmann A, Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Exp Rev Neurother 2013; 13: 313-35.
[8]
Knier B, Hemmer B, Korn T. Novel monoclonal antibodies for therapy of multiple sclerosis. Expert Opin Biol Ther 2014; 14: 503-13.
[9]
Gupta S, Weinstock-Guttman B. Natalizumab for multiple sclerosis: appraising risk versus benefit, a seemingly demanding tango. Expert Opin Biol Ther 2014; 14: 115-26.
[10]
McCormack PL. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis. Drugs 2013; 73: 1463-81.
[11]
Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol 2012; 71: 604-17.
[12]
Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord 2015; 8: 31-45.
[13]
Hartung HP, Aktas O, Boyko AN. Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis. Mult Scler 2015; 21: 22-34.
[14]
Jones DE, Goldman MD. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety. Exp Rev Clin Immunol 2014; 10: 1281-91.
[15]
Tuohy O, Costelloe L, Hill-Cawthorne G, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry 2015; 86: 208-15.
[16]
Willis MD, Robertson NP. Alemtuzumab for the treatment of multiple sclerosis. Ther Clin Risk Manag 2015; 11: 525-34.
[17]
Hersh CM, Cohen JA. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Immunotherapy 2014; 6: 249-59.
[18]
D’Amico E, Messina S, Caserta C, Patti F. A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. Expert Opin Drug Saf 2015 Mar 31; 1-12. [Epub ahead of print].
[19]
Oh J, Saidha S, Cortese I, et al. Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis. Neurology 2014; 82: 984-8.
[20]
Martin R. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin Immunol 2012; 142: 9-14.
[21]
Melcon MO, Melcon CM, Bartoloni L, et al. Towards establishing MS prevalence in Latin America and the Caribbean. Mult Scler 2013; 19: 145-52.